Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Vulvovaginal Candidiasis | Correction

Correction to: Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis

Authors: Yu Shi, Yuxia Zhu, Shangrong Fan, Xiaoping Liu, Yiheng Liang, Yingying Shan

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Excerpt

Following publication of the original article [1], the authors identified an error in Table 3. The correct table (Table 3) is given in this erratum and the original article has been corrected.
Table 3
In vitro antifungal susceptibility of 1844 clinical isolates of Candida species as determined by the CLSI method
Candida species (n)
Antifungal agents
 
BUC
CLO
FLC
ITC
MIC
TEC
VRC
C. lusitaniae, n = 1
Range
0.03
0.03
0.125
0.03
0.03
0.03
0.03
C. Fabianii, n = 3
Range
0.03–0.25
0.03–0.06
0.5–1
0.03–0.25
0.125–1
0.03
0.03
MIC50
0.125
0.03
0.5
0.06
0.125
0.03
0.03
MIC90
0.25
0.06
1
0.25
1
0.03
0.03
Trichosporon asahii, n = 1
Range
0.03
0.03
0.25
0.03
0.06
0.03
0.03
Rhodotorula, n = 3
Range
0.03–0.5
0.03–1
4–128
0.03–8
0.25–8
0.03–0.5
0.03–1
MIC50
0.06
0.06
64
2
1
0.06
0.03
MIC90
0.5
1
128
8
8
0.5
1
Kodamaea ohmeri, n = 2
Range
0.125–0.5
0.03
0.25–2
0.125–0.25
0.25–0.5
0.03
0.03
MIC50
0.125
0.03
0.25
0.125
0.25
0.03
0.03
MIC90
0.5
0.03
2
0.25
0.5
0.03
0.03
Issatchenkia terricola, n = 2
Range
1–4
0.06–0.125
32–64
0.25–0.5
0.5
0.25
0.25
MIC50
1
0.06
32
0.25
0.5
0.25
0.25
MIC90
4
0.125
64
0.5
0.5
0.25
0.25
Torulaspora pretoriensis, n = 1
Range
0.25
0.03
8
0.5
0.5
0.125
0.125
ATCC90028*
Range
0.015–0.5
0.015–0.5
0.125–2
0.015–4
0.008–0.015
0.015–32
0.015–8
GM
0.04
0.03
0.21
0.08
0.06
0.03
0.03
MIC90
0.125
0.03
0.5
0.25
0.015
0.03
0.03
Candida species (n)
Antifungal agents
   
AmB
FLU
NYS
TEB
AFG
CFG
MFG
C. albicans
n = 1272
Range
0.015–32
0.03–128
0.03–32
0.03–256
0.008–0.5
0.008–0.5
0.008–0.5
 
GM
0.22
0.70
1.60
45.11
0.015
0.1
0.03
 
MIC90
0.5
4
8
256
0.03
0.25
0.25
 
R
 
3.3%
   
0
0
0
C. africana
n = 49
Range
0.03–32
0.06–8
0.125–4
0.25–256
0.008–0.03
0.015–0.5
0.008–0.5
 
GM
0.08
0.68
0.5
17.31
0.01
0.06
0.02
 
MIC90
1
2
4
128
0.015
0.25
0.06
C. dubliniensis
n = 1
Range
0.06
0.06
0.25
16
0.008
0.015
0.008
C. glabrata
n = 267
Range
0.03–2
0.06–16
0.03–32
0.25–256
0.008–0.5
0.008–0.5
0.008–0.5
 
GM
0.29
0.18
3.39
26.62
0.03
0.11
0.05
 
MIC90
1
1
8
256
0.06
0.25
0.25
 
R
 
0
   
0
0
0
C. nivariensis
n = 9
Range
0.06–2
0.125–4
0.5–4
1–256
0.015–0.06
0.08–0.5
0.015–0.5
 
MIC50
0.06
0.5
1
128
0.06
0.25
0.015
 
MIC90
2
2
4
256
0.06
0.5
0.5
C. bracarensis
n = 2
Range
0.06–1
0.125–2
0.25–8
8–256
0.015–0.03
0.125–0.5
0.015–0.5
 
MIC50
0.06
0.125
0.25
8
0.015
0.125
0.015
 
MIC90
1
2
8
256
0.03
0.5
0.5
C. parapsilosis
n = 76
Range
0.03–2
0.125–8
0.03–32
0.25–256
0.008–1
0.008–1
0.008–1
 
GM
0.19
0.14
0.59
0.62
0.69
0.60
0.54
 
MIC90
1
0.125
4
32
0.5
0.5
0.5
 
R
 
0
   
5.2%
5.2%
1.3%
C. metapsilosis
n = 20
Range
0.015–0.5
0.125–4
0.06–4
0.25–256
0.015–0.5
0.008–0.5
0.015–1
 
GM
0.10
0.177
0.46
2.17
0.17
0.17
0.39
 
MIC90
0.5
1
4
256
0.25
0.25
0.5
Candida species (n)
Antifungal agents
   
AmB
FLU
NYS
TEB
AFG
CFG
MFG
C. orthopsilosis
n = 6
Range
0.06–0.25
0.125–2
0.06–8
0.25–128
0.008–1
0.015–1
0.008–0.5
 
MIC50
0.125
1
0.5
64
0.08
0.30
0.25
 
MIC90
0.25
2
8
128
1
1
0.5
C. tropicalis
n = 61
Range
0.03–1
0.125–32
0.03–8
0.25–256
0.015–0.125
0.008–0.5
0.008–0.5
 
GM
0.19
0.23
0.54
60.02
0.03
0.24
0.04
 
MIC90
0.5
1
4
256
0.06
0.5
0.5
 
R
 
1.8%
   
0
0
0
C. krusei
n = 54
Range
0.03–1
0.125–32
0.03–4
16–256
0.015–0.5
0.008–1
0.008–0.5
 
GM
0.43
4.2
0.32
75.66
0.08
0.08
0.15
 
MIC90
1
16
1
256
0.125
0.5
0.25
 
R
 
2.9%
   
0
1.85%
0
Saccharomyces cerevisiae
n = 12
Range
0.03–4
0.06–8
0.125–32
0.25–256
0.015–0.5
0.08–0.5
0.015–0.5
 
GM
0.18
0.21
0.78
53.20
0.14
0.10
0.18
 
MIC90
1
1
8
256
0.5
0.25
0.25
C. guilliermondii
n = 2
Range
0.06–0.5
0.125–0.25
0.25–0.5
64–128
0.015–0.25
0.25–0.5
0.015–0.25
 
MIC50
0.06
0.125
0.25
64
0.015
0.25
0.015
 
MIC90
0.5
0.25
0.5
128
0.25
0.5
0.25
 
R
 
0
   
0
0
0
C. lusitaniae
n = 1
Range
0.125
0.125
0.25
0.25
0.03
0.25
0.015
C. fabianii
n = 3
Range
0.06–0.25
0.125
0.25
128
0.015–0.03
0.015–0.25
0.015–0.06
 
MIC50
0.06
0.125
0.25
128
0.015
0.015
0.03
 
MIC90
0.25
0.125
0.25
128
0.03
0.25
0.06
Trichosporon asahii
n = 1
Range
0.125
1
0.25
128
0.015
0.5
0.015
Rhodotorula
n = 3
Range
0.03–0.5
0.125
0.06–0.125
8–256
0.06–0.5
0.25–0.5
0.25–0.5
 
MIC50
0.03
0.125
0.06
8
0.06
0.25
0.25
 
MIC90
0.5
0.125
0.125
256
0.5
0.5
0.5
Kodamaea ohmeri
n = 2
Range
0.125–1
0.125
0.5
128
0.015
0.125–0.25
0.015–0.03
 
MIC50
0.125
0.125
0.5
128
0.015
0.125
0.015
 
MIC90
1
0.125
0.5
128
0.015
0.25
0.03
Issatchenkia terricola
n = 2
Range
0.125–0.5
8
0.5
128–256
0.06
0.06
0.08
 
MIC50
0.125
8
0.5
128
0.06
0.06
0.08
 
MIC90
0.5
8
0.5
256
0.06
0.06
0.08
Torulaspora pretoriensis
n = 1
Range
0.125
0.125
0.25
16
0.015
0.125
0.015
ATCC90028a
Range
0.03–2
0.125–8
0.25–16
1–256
0.008–0.015
0.015–0.5
0.008–0.015
 
GM
0.22
0.64
1.31
88.22
0.01
0.09
0.01
 
MIC90
1
2
8
256
0.015
0.5
0.015
GM geometry mean, BUC butoconazole, CLO Clotrimazole, FLC Fluconazole, ITC Itraconazole, VRC Voriconazole, MIC Miconazole, TEC Terconazole, AmB Amphotericin B, FLU Flucytosine, NYS Nystatin, TEB Terbinafine, AFG Anidulafungin, CFG Caspofungin, MFG Micafungin
aATCC90028 was tested 57 times
…
Literature
1.
Metadata
Title
Correction to: Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis
Authors
Yu Shi
Yuxia Zhu
Shangrong Fan
Xiaoping Liu
Yiheng Liang
Yingying Shan
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06601-x

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue

Research

Evolution and spread of a highly drug resistant strain of Mycobacterium tuberculosis in Papua New Guinea

Research

The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs

Research article

Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting

Research

Transmission risk of COVID-19 in high school and college water polo

Research

Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: a retrospective observational study

Research article

Comparison of clinical characteristics and outcomes of hospitalized patients with seasonal coronavirus infection and COVID-19: a retrospective cohort study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits